Removal of Carbamazepine in Aqueous Solution by CoS2/Fe2+/PMS Process

Carbamazepine (CBZ), as a typical pharmaceutical and personal care product (PPCP), cannot be efficiently removed by the conventional drinking water and wastewater treatment process. In this work, the CoS₂/Fe²⁺/PMS process was applied for efficient elimination of CBZ. The CBZ removal efficiency of CoS₂/Fe²⁺/PMS was 2.5 times and 23 times higher than that of CoS₂/PMS and Fe²⁺/PMS, respectively. The intensity of DMPO-HO• and DMPO-SO4•− followed the order of Fe²⁺/PMS < CoS₂/PMS < CoS₂/Fe²⁺/PMS, also suggesting the CoS₂/Fe²⁺/PMS process has the highest oxidation activity. The effects of reaction conditions (e.g., CoS₂ dosage, Fe²⁺ concentration, PMS concentration, initial CBZ concentration, pH, temperature) and water quality parameters (e.g., SO42−, NO3−, H2PO4−, Cl−, NH4+, humic acid) on the degradation of CBZ were also studied. Response surface methodology analysis was carried out to obtain the best conditions for the removal of CBZ, which are: Fe²⁺ = 70 µmol/L, PMS = 240 µmol/L, CoS₂ = 0.59 g/L. The sustainability test demonstrated that the repeated use of CoS₂ for 8 successive cycles resulted in little function decrease (<10%). These findings suggest that CoS₂/Fe²⁺/PMS may be a promising method for advanced treatment of tailwater from sewage treatment plant.     

兔VX2移植肝癌及隔离灌注模型建立方法探究

应用开腹瘤块包埋法建立了兔移植肝癌模型,探讨了改良动脉插管技术及提高隔离灌注模型建立的成功率.采用的方法是将实验兔建立移植肝癌模型10d后,按动脉插管方法随机分为3组：A组为直视下儿科静脉留置针插管;B组为显微镜下儿科静脉留置针插管;C组为直视下硬膜外麻醉导管插管.建模成功后经肝动脉灌注奥沙利铂,隔离灌注模型建立前测量肿瘤生长大小,常规病理观察肿瘤,比较插管成功率.研究结果表明：肿瘤生长良好,应用儿科静脉留置针插管成功率明显高于硬膜外麻醉导管,显微镜下插管较直视下无统计学意义,奥沙利铂浓度外周静脉显著低于流出道.由此认为采用儿科静脉留置针插管操作简单,成功率高,建立隔离灌注模型外周血药物泄漏少,阻断较完全,是一种实用的隔离灌注建立方法.     

铬硅薄膜电阻的退火工艺条件研究

分析了CrSi薄膜电阻阻值的变化机理,并以此作为理论指导,开展退火工艺条件对铬硅薄膜电阻稳定性影响的实验,得到优化的退火工艺条件,可以使铬硅薄膜电阻的温度系数减小到±0.0001℃左右,大大提高了铬硅薄膜电阻的稳定性。     

一维声子晶体杆状结构纵向振动带隙特性

基于传递矩阵法,以一维声子晶体杆状结构纵向振动带隙特性为研究对象,应用MATLAB编程,数值模拟了A为金、铜、铝和碳,B为环氧树脂时纵向振动带隙特性,得到铜与与环氧树脂构成一维声子晶体时,形成最大振动带隙宽度3．39KHz ,其中金能够形成较多的带隙区间。数值模拟了A为铜,B为硅橡胶、有机玻璃1、有机玻璃2和塑料时,得到A为铜,B为塑料时形成最大带隙在0．51KHz -7．06KHz ,带隙宽度为6．55KHz ,这两种组合形成了最大带隙宽度。A为铜,B为有机玻璃1时形成较多的带隙结构。研究结论为一维声子晶体器件制作提供参考。     

用单端矢量网络分析仪测试手机RF电路的差分散射参数

本文以声表的测试为例,说明了采用单端矢量网络分析仪测试手机射频(RF)电路的差分散射参数的原理及方法,其中包含物理三端口的散射参数和模式三端口网络散射参数。     

激光处理对油松种子活力指数的影响

用激光分别处理油松干、湿种子,干种子发芽率与活力指数分别为对照组的 １３６％ 和 １６７％ ,浸水 ３６ｈ后的湿种子发芽率与活力指数分别为对照组的 １３７％ 和 １５９％ 。     

基于ANSYS管道检测系统转子静动态特性分析

为研究旋转探头管道超声检测系统转子静态特性和动态特性,建立了简化的转子的有限元模型,并应用有限元分析软件ANSYS对转子进行静态分析、模态分析和谐响应分析,得到了转子结构应力、变形云图和前六阶固有频率。分析结果说明转子的静刚度和动刚度符合检测系统设计要求,验证了转子结构设计的合理性,为检测系统转子的设计提供的可靠的评价依据。     

电子战半实物仿真系统

介绍了Windows NT RTX及广播内存网在实时性方面的特点及其软硬件组成,对电子战系统的半实物仿真进行了详细综述,阐明了电子战半实物仿真系统的系统构成,并对系统的各组成部分进行了讨论。     

计算串联稳压电路调整管的最大功耗的另一种方法

串联稳压电路主要工作在线性状态,因此调整管的功耗大。很多情况下调整管的损坏系因其功耗过大发热所致,所以计算调整管的最大功耗是选择调整管的关键,但一些教材中对调整管功耗的计算方法不够严密。本文利用最大功率传递定理,对调整管的最大功耗进行了分析计算。     

In Vitro–In Vivo Correlation of Tianeptine Sodium Sustained-Release Dual-Layer Tablets

Tianeptine tablets are currently marketed to be designed for immediate-release tablets. The tianeptine has a short half-life, making it difficult to design for sustained-release tablets and achieve bioequivalence with the tianeptine immediate-release tablet (Stablon^®). We established the in vitro–in vivo correlation (IVIVC) of three formulations of tianeptine sustained-release tablets according to their granule size. To evaluate sustained drug release, in vitro tests were performed in pH 1.2 media for 24 h. In vivo pharmacokinetic analysis was performed following oral administration of reference drug and test drug to beagle dogs. The dissolution profile revealed delayed release as the size of the granules increased. The dissolution results were confirmed in pharmacokinetic analysis, showing that the half-life was delayed as granule size increased. The final formulation and reference drug showed an equivalent area under the curve (AUC). Through this, IVIVC was established according to the size of the tianeptine sodium granules, which is the purpose of this study, and was used to predict in vivo pharmacokinetics from the formulation composition. This approach may be useful for determining optimal formulation compositions to achieve the desired pharmacokinetics when developing new formulations.